HAEM5:Juvenile xanthogranuloma: Difference between revisions
| [pending revision] | [pending revision] |
mNo edit summary |
mNo edit summary |
||
| Line 135: | Line 135: | ||
|Unknown | |Unknown | ||
|Unknown | |Unknown | ||
| | |Disseminated JXG with ''GAB2::BRAF'' fusion showed favorable response to treatment with Trametinib (MEK1/2 inhibitor). [5]. | ||
Disseminated JXG with ''GAB2::BRAF'' fusion showed favorable response to treatment with Trametinib (MEK1/2 inhibitor). [5]. | |BRAF gene fusions are more often seen in adult and Juvenile JXG as compared with other histiocytic disorders. [10] | ||
|BRAF gene fusions are more often seen in adult and Juvenile JXG as compared with other histiocytic disorders. [10] | |||
|- | |- | ||
|RET fusions | |RET fusions | ||
| Line 173: | Line 172: | ||
|- | |- | ||
|''MRC1-PDGFRB'' fusion | |''MRC1-PDGFRB'' fusion | ||
|t(5;10)(q32; p12.33) translocation | |t(5;10)(q32; p12.33) translocation | ||
|in-frame ''MRC1-PDGFRB'' gene fusion | |in-frame ''MRC1-PDGFRB'' gene fusion | ||
Can be seen with large deletion of exons 21 and 22 [12] | Can be seen with large deletion of exons 21 and 22 [12] | ||
| Line 248: | Line 247: | ||
|- | |- | ||
|5 | |5 | ||
|Gain, Heterozygosity | |Gain, Heterozygosity | ||
|Unknown | |Unknown | ||
|Unknown | |Unknown | ||